Answers are grounded in this paper and cite their sources.
PARP inhibitors are currently one of the most promising PARP targeted drugs for patients with certain types of cancer. Gastrointestinal (GI) events are common adverse events for all PARP inhibitors. We conducted this meta‐analysis of randomized controlled trials (RCTs) to fully investigate the incidence and the relative risk of GI events in cancer patients receiving PARP inhibitors.
No takes yet. Share an insight, caveat, or question.
Sun et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: